From The Conversation, guest author Laura Bisaillon on rampant HIV discrimination through the immigration process.
Are you kidding me? With nearly four decades under our collective belts of global experience working on HIV and AIDS, we are past considering it acceptable to link someone’s health status with their perceived sexual “moral values.”
Such were my thoughts after reading and reflecting on an article in The Toronto Star this month: “Decision-maker slammed as ‘Moral Police’ for refusing immigration to HIV-positive man.”
I have researched medical inadmissibility decision-making and
From Overland, guest author Daniel Reeders: "... messages on sexual health almost invariably focus on sex rather than health."
Image credit: Reginald Mount, ‘The easy girlfriend’ (poster), Norwich: Her Majesty’s Stationery Office, 1943-44. This file comes from Wellcome Images, a website operated by Wellcome Trust, a global charitable foundation based in the United Kingdom. Refer to Wellcome blog post (archive).
This article by Daniel Reeders previously appeared at Overland, here.
Two or three times a year, there’ll be a major conference on sexual health, or a report released on how many new sexually tr
Indigenous, Latino, bisexual and single men less likely to be aware of newly publicly-funded HIV prevention medication
(Vancouver, January 31, 2018) A new study shows most of gay, bi, men who have sex with men (MSM) and other MSM, are aware of PrEP (pre-exposure prophylaxis) - an HIV prevention drug recently made available at no charge to British Columbians at risk of HIV - according to the Momentum Health Study at the BC Centre for Excellence in HIV/AIDS.
“Gay, bisexual, MSM and other MSM in Canada accounted for 56.8% of all new cases of HIV in Canada,” says research scientist, Nathan Lachowsky. “Incre
Closures have taken place across central London and remaining clinics across the capital are facing unmanageable demands. From the Evening Standard, Eleanor Rose reports.
Testing: Digital services will allow people to carry out tests at home, but the rollout has been delayed.
To read the complete story by Eleanor Rose, visit The Evening Standard, here.
Up to 600 people per week are being turned away from oversubscribed sexual health clinics at one of London’s NHS trusts, an expert has warned. Dr Mark Lawton of the British Association of Sexual Health and HIV said the data showing hundreds of people are being turned away from clinic at Guy’s and St Tho
The breadth of data being collected is intended to help answer the wide range of questions about what “real-world” PrEP use looks like in the province. Jack Mohr of the Ontario PrEP Cohort Study has this report.
After years spent waiting, more widespread access to Pre-Exposure Prophylaxis (PrEP) in Ontario finally seems to be taking shape. Health Canada approval for generic forms of tenofovir disoproxil fumarate/emtricitabine (the drug combination used for PrEP) has drastically decreased out of pocket costs for PrEP. This development, along with concerted lobbying from HIV activists, also led to the addition of PrEP to the Ontario Drug Benefit formulary in September 2017. While these changes don’t
From the National Institutes of Health: NIH clinical trial is testing antibody against the protein in people with HIV.
For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes. Previous research illustrated this relationship in monkeys infected with a simian form of HIV.
The new study found that women who had more CD4+ T cells displaying high levels of alpha-4 beta-7 on their surface were more likely to become infected with HIV, and the virus damage
Toxicity and patient factors were the main reasons why women did not receive treatment recommended in guidelines.From AIDSmap, Michael Carter reports.
The majority of HIV-positive women diagnosed with gynaecological cancer do not receive treatment recommended by cancer guidelines, according to research conducted in the United States and published in AIDS. Women whose care did not match guideline standards had poorer survival compared to women who received the recommended care. Toxicity and patient factors were the main reasons why women did not receive treatment recommended in guidelines.
“To our knowledge, there is no case series de
Please sign this petition calling for GIPA to be acknowledged in HIV research findings
The partnerships forged between people living with HIV and researchers have been an essential foundation upon which the response to the HIV epidemic has grown and the time has come to reaffirm and recommit to principles of inclusion and respect in the conduct of presenting research findings that impacts on our lives.
The early years of the HIV epidemic ushered in a radically different approach to traditional medical and clinical research. Academics and activists held a shared understanding th
Hear an update of how Toronto can end HIV transmissions.
Leading Toronto researchers and clinicians invite you to a discussion of how HIV prevention tools are improving and combine to get us to zero new infections.
(Speakers: Sharmistha Mishra, Rupert Kaul, Malika Sharma, Beth Rachlis, Taylor Sicard, Isaac Bogoch, Abigail Kroch. Moderator: R. Reinhard)
When: Wednesday, February 7, 2018 6:30-8:30 PM
Where: Hart House Music Room (U. of Toronto campus)
Elevator and access ramp accessible. Light refreshments will be provided.
Please RVSP by email
From The Conversation, Dennis Altman: "Desire, behaviour and identity are distinct, and do not always overlap."
This article by Dennis Altman prevously appeared at The Conversation, here.
The rise of sexually transmissible diseases made front-page news in The Age, which tried to make sense of the rise among “gay men” and “heterosexual people”.
This illustrates the increasingly common confusion between behaviour and identity. What is involved is sexual contact, or to use the expression common in the early days of the AIDS epidemic, “the exchange of bodily fluids”. Whether people involve
“Our results show that any detectable viral load between 51 and 999 copies per ml leads to poorer treatment outcomes than successful virological suppression of less than 50 copies per ml,” write the investigators. From AIDSmap, Keith Alcorn reports.
Low-level HIV viral load, above the limit of detection, is an important warning signal for future treatment failure and World Health Organization guidelines on spotting treatment failure need to be revised to encourage greater vigilance and swifter action by healthcare providers in lower- and middle-income settings, investigators report in The Lancet Infectious Diseases.
The study, carried out by Annemarie Wensing and colleagues at the University of Utrecht in the Netherlands and University
From FS Magazine, Hadley Stewart: "Despite having consented to sex, we don’t necessarily make it clear what we’re consenting to. How able do you feel to negotiate in the bedroom?"
If, like me, you’ve never sat down and thought about the term ‘consent’, you’d be forgiven for thinking that it doesn’t really apply to you.
Often we associate the term with the law, meaning that it’s easy to think it’s something that doesn’t form part of our lives unless we’ve been the victim of a crime. A sexual assault, for instance, is often paired up with the notion of consent. So does that mean we’ve never consented to anything or used our power of consent? Probably
From NAM aidsmap, Roger Pebody reports on two studies, one using long-acting injectables as TasP and one using them as PrEP.
HIV-positive people who took injectable cabotegravir + rilpivirine every four or eight weeks as antiretroviral therapy found it more convenient and discreet than daily pills, also feeling that it eliminated a “daily reminder of living with HIV”, Deanna Kerrigan and colleagues report in PLOS One.
Similarly, HIV-negative men who took injectable cabotegravir every 12 weeks as pre-exposure prophylaxis (PrEP) felt that it was probably more convenient and easier to adhere to than dai
Research indicates alternative contraception methods may help protect women.
Washington, DC - Transitioning away from a popular contraceptive shot known as DMPA could help protect women in Sub-Saharan Africa and other high-risk regions from becoming infected with HIV, according to a research review published in the Endocrine Society’s journal Endocrine Reviews.
The predominant contraceptive in Sub-Saharan Africa is depot-medroxyprogesterone acetate (DMPA)—a birth control shot administered every three months. Human studies suggest DMPA use may raise the risk of H